Archive

HIGHLIGHTS

 
LSP Life Sciences Fund makes 250% on Ablynx sale
To read the full article click here.
 
Her Majesty Queen Máxima launches Oncode Institute, founded by LSP's Rudy Dekeyser and René Kuijten
Oncode Institute combines 600 of the very best oncology researchers with a highly qualified valorisation staff to ensure that breakthrough discoveries get to patients faster.    The origins of Oncode go back[...]
 
LSP reaches milestone: 10 years investing in listed Life Sciences Securities
LSP Life Sciences Fund generates net return of 39% in 2017   Amsterdam, January 16 2018 - LSP, the European life sciences investment group, today announced it has reached its 10 year milestone investing in li[...]
 
LSP invests in Simplify Medical to bring the company’s innovative cervical disc to the US Market
Amsterdam, the Netherlands - 12 February 2018 - LSP announces its investment in Simplify Medical. The LSP Health Economics Fund 2 (LSP HEF 2) leads the second tranche of the company’s Series B financing of $23.5 mil[...]
 
Takeda to acquire LSP portfolio company TiGenix
Takeda announces its intention to acquire TiGenix   Leuven (BELGIUM) - January 5, 2018, 7:30h CET - TiGenix NV ("TiGenix") (Euronext Brussels and NASDAQ: "TIG"), an advanced biopharmaceutical company focused [...]
 
LSP Raises EUR 280 Million to Invest In Healthcare Innovation
Largest fund in Europe dedicated to medical technology Significant fundraise reflects successful investment strategy to achieve better care at lower costs   Amsterdam, 12 December 2017 – LSP, the Europe[...]
 
Marco Groot over LSP in het FD
Amsterdam, April 11, 2017 Marco Groot over LSP in het FD Lees de gehele column: Een absoluut beter resultaat   Amsterdam, July 11, 2017: Marco Groot blikt in het FD terug op zijn eerdere positiev[...]
 
LSP leads EUR 27 mln Series A financing of new VIB start-up Aelin Therapeutics to exploit its proprietary Pept-in™ protein knockdown platform
Leuven, Belgium – 11 December 2017 – Aelin Therapeutics, a privately held Belgian biotherapeutics company, announces today that it has secured a EUR 27 million investment to pioneer a novel modality in drug develo[...]
 
LSP FUNDRAISING NEWS
LSP announces EUR 250 mln final closing of LSP 5
 
LSP RECOMMENDS
LSP Partner Clemens van Blitterswijk gives a TedX on the future of regenerative medicine
 
BioCentury: LSP's Four of a Kind
To read the full article click here
 
Is a cure for cancer finally within reach?
To read the full article click here
 
argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis
Favorable tolerability profile consistent with Phase 1 data ARGX-113 treatment resulted in a strong clinical improvement over placebo during the entire duration of the study  75% of ARGX-113 treated p[...]

2018


Merus Announces $55.8 Million Private Placement Offering of Common Stock
UTRECHT, The Netherlands, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that [...]
LSP invests in Simplify Medical to bring the company’s innovative cervical disc to the US Market
Amsterdam, the Netherlands - 12 February 2018 - LSP announces its investment in Simplify Medical. The LSP Health Economics Fund 2 (LSP HEF 2) leads the second tranche of the company’s Series B financing of $23.5 mil [...]
Her Majesty Queen Máxima launches Oncode Institute, founded by LSP's Rudy Dekeyser and René Kuijten
Oncode Institute combines 600 of the very best oncology researchers with a highly qualified valorisation staff to ensure that breakthrough discoveries get to patients faster.    The origins of Oncode go back [...]
LSP Life Sciences Fund makes 250% on Ablynx sale
To read the full article click here. [...]
Merus Announces First Patient Dosed in a Phase 2 Clinical Trial of MCLA-128 in Two Metastatic Breast Cancer Patient Populations
Combination trial to evaluate MCLA-128 in HER2-positive and hormone receptor-positive/HER2-low metastatic breast cancer patients   UTRECHT, the Netherlands, Jan. 26, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasda [...]
BioCapital Europe 2018, organised by LSP
BioCapital Europe 2018, an LSP (Life Sciences Partners) event, is delighted to announce its 16th consecutive event, taking place on 6th February 2018 in Amsterdam, The Netherlands. BioCapital Europe is Europe’s prem [...]


2018
2017
2016
2015
2014
2013
2012
back to news overview
Follow us

Archive

HIGHLIGHTS

 
LSP Life Sciences Fund makes 250% on Ablynx sale
To read the full article click here.
 
Her Majesty Queen Máxima launches Oncode Institute, founded by LSP's Rudy Dekeyser and René Kuijten
Oncode Institute combines 600 of the very best oncology researchers with a highly qualified valorisation staff to ensure that breakthrough discoveries get to patients faster.    The origins of Oncode go back[...]
 
LSP reaches milestone: 10 years investing in listed Life Sciences Securities
LSP Life Sciences Fund generates net return of 39% in 2017   Amsterdam, January 16 2018 - LSP, the European life sciences investment group, today announced it has reached its 10 year milestone investing in li[...]
 
LSP invests in Simplify Medical to bring the company’s innovative cervical disc to the US Market
Amsterdam, the Netherlands - 12 February 2018 - LSP announces its investment in Simplify Medical. The LSP Health Economics Fund 2 (LSP HEF 2) leads the second tranche of the company’s Series B financing of $23.5 mil[...]
 
Takeda to acquire LSP portfolio company TiGenix
Takeda announces its intention to acquire TiGenix   Leuven (BELGIUM) - January 5, 2018, 7:30h CET - TiGenix NV ("TiGenix") (Euronext Brussels and NASDAQ: "TIG"), an advanced biopharmaceutical company focused [...]
 
LSP Raises EUR 280 Million to Invest In Healthcare Innovation
Largest fund in Europe dedicated to medical technology Significant fundraise reflects successful investment strategy to achieve better care at lower costs   Amsterdam, 12 December 2017 – LSP, the Europe[...]
 
Marco Groot over LSP in het FD
Amsterdam, April 11, 2017 Marco Groot over LSP in het FD Lees de gehele column: Een absoluut beter resultaat   Amsterdam, July 11, 2017: Marco Groot blikt in het FD terug op zijn eerdere positiev[...]
 
LSP leads EUR 27 mln Series A financing of new VIB start-up Aelin Therapeutics to exploit its proprietary Pept-in™ protein knockdown platform
Leuven, Belgium – 11 December 2017 – Aelin Therapeutics, a privately held Belgian biotherapeutics company, announces today that it has secured a EUR 27 million investment to pioneer a novel modality in drug develo[...]
 
LSP FUNDRAISING NEWS
LSP announces EUR 250 mln final closing of LSP 5
 
LSP RECOMMENDS
LSP Partner Clemens van Blitterswijk gives a TedX on the future of regenerative medicine
 
BioCentury: LSP's Four of a Kind
To read the full article click here
 
Is a cure for cancer finally within reach?
To read the full article click here
 
argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis
Favorable tolerability profile consistent with Phase 1 data ARGX-113 treatment resulted in a strong clinical improvement over placebo during the entire duration of the study  75% of ARGX-113 treated p[...]

$smarty.now|date_format:"%Y"


Merus Announces $55.8 Million Private Placement Offering of Common Stock
UTRECHT, The Netherlands, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that [...]
LSP invests in Simplify Medical to bring the company’s innovative cervical disc to the US Market
Amsterdam, the Netherlands - 12 February 2018 - LSP announces its investment in Simplify Medical. The LSP Health Economics Fund 2 (LSP HEF 2) leads the second tranche of the company’s Series B financing of $23.5 mil [...]
Her Majesty Queen Máxima launches Oncode Institute, founded by LSP's Rudy Dekeyser and René Kuijten
Oncode Institute combines 600 of the very best oncology researchers with a highly qualified valorisation staff to ensure that breakthrough discoveries get to patients faster.    The origins of Oncode go back [...]
LSP Life Sciences Fund makes 250% on Ablynx sale
To read the full article click here. [...]
Merus Announces First Patient Dosed in a Phase 2 Clinical Trial of MCLA-128 in Two Metastatic Breast Cancer Patient Populations
Combination trial to evaluate MCLA-128 in HER2-positive and hormone receptor-positive/HER2-low metastatic breast cancer patients   UTRECHT, the Netherlands, Jan. 26, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasda [...]
BioCapital Europe 2018, organised by LSP
BioCapital Europe 2018, an LSP (Life Sciences Partners) event, is delighted to announce its 16th consecutive event, taking place on 6th February 2018 in Amsterdam, The Netherlands. BioCapital Europe is Europe’s prem [...]


2018
2017
2016
2015
2014
2013
2012
back to news overview